SCHEMBL19365866

SCHEMBL19365866

NCCCCCC(=O)NCc1cccc(NC(=O)N(c2nc(-c3cccc(C(F)(F)F)c3)ccc2N)C2CCC2)c1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ DCUN1D1 Q96GG9 10/20 0.37
▸ HDAC3 O15379 2/20 0.37
▸ HDAC1 Q13547 2/20 0.37
▸ HDAC2 Q92769 1/20 0.37
▸ HDAC10 Q969S8 1/20 0.37
▸ HDAC11 Q96DB2 1/20 0.37
▸ HDAC8 Q9BY41 1/20 0.37
▸ HDAC6 Q9UBN7 1/20 0.37
▸ NCOR2 Q9Y618 1/20 0.37
▸ BACE1 P56817 1/20 0.37
▸ UBE2M P61081 7/20 0.36
▸ TP53 P04637 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ CYP3A4 P08684 1/20 0.35
▸ VCP P55072 1/20 0.35
▸ SMYD3 Q9H7B4 1/20 0.35
▸ MPO P05164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19365784 0.85 POLB (0.47) POLBRAB9ADCUN1D1UBE2M
SCHEMBL19365722 0.82 POLB (0.41) POLBRAB9ADCUN1D1HDAC1BACE1
SCHEMBL19365306 0.80 POLB (0.44) POLBRAB9ADCUN1D1HDAC1BACE1
SCHEMBL19670560 0.80 POLB (0.47) POLBRAB9ATP53MAPT
SCHEMBL19365835 0.79 CNR2 (0.53) DCUN1D1UBE2M
SCHEMBL19706120 0.78 POLB (0.45) POLBRAB9ADCUN1D1UBE2MTP53
SCHEMBL19365828 0.77 CA12 (0.46) DCUN1D1HDAC1VCP
SCHEMBL19365636 0.77 POLB (0.46) POLBRAB9ADCUN1D1UBE2M
SCHEMBL19365519 0.77 POLB (0.46) POLBRAB9ADCUN1D1HDAC3HDAC1
SCHEMBL19706296 0.76 POLB (0.39) POLBRAB9ADCUN1D1HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2020-03-17 — — US disclosed
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2017-12-14 — — US disclosed
US-9834558-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-12-05 — — US disclosed
US-9765075-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-09-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 POLB 961/4885RAB9A 1471/4885DCUN1D1 1730/4885
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators SIRT1, SIRT3, SIRT2 POLB 961/4885RAB9A 1471/4885DCUN1D1 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback